SWEEP
25.5.2023 00:02:32 CEST | Business Wire | Press release
Sweep, the leading carbon and ESG management platform, today launched Sweep for Compliance, the first solution for reliable, transparent, and audit-ready reporting in compliance with the EU’s new Corporate Sustainability Reporting Directive (CSRD).
By 2025, an estimated 50,000 European Union businesses and at least 10,000 EU-based foreign companies will be falling under the scope of the CSRD, requiring them to communicate their 2024 extra-financial information. Globally, a rising number of sustainability disclosure regulations demand companies and financial institutions to track and publicly communicate new sets of data. If companies fail to act, they face compliance risks, such as financial sanctions, legal penalties, and damaging greenwashing accusations.
But, measuring ESG and carbon data is complex and time consuming without the right technology. Two-thirds (65%) of French business leaders believe their organization is not sufficiently prepared to meet ESG objectives, nor to fulfill regulatory requirements according to Workiva. Sweep for Compliance helps businesses easily comply with the right ESG, carbon, and regulatory disclosure requirements using advanced data analytics and reporting requirements directly embedded into the platform.
“In 2023, data collection can’t be a bottleneck for companies to track and improve their positive impact. Monitoring extra financial data is now a crucial business issue as European sustainability regulations become more stringent. Sweep for Compliance gives CFOs, CSOs, and auditors the most advanced tools to measure carbon and ESG data and comply with upcoming legislation,” says Rachel Delacour, CEO and Cofounder at Sweep.
Sweep for Compliance streamlines the disclosure exercise, from data gathering and quality checks, traceability and monitoring, to generating insights and in-depth reports. With up to 50% time saved in the auditing process, it ensures consistent, verified, and compliant ESG and carbon data reporting in one click. It’s the only solution on the market to help companies get ready and stay on track with disclosure requirements.
“With the growing number of sustainability regulations and stakeholder demands for transparency, companies are under pressure to accurately communicate their impact. By working with tech partners like Sweep, large organizations can streamline the collection, monitoring, and reporting of their non financial data in one single place,” says Jérémie Joos, Co-Head of ESG Center of Excellence at KPMG France.
Sweep is the trusted data partner for companies such as pet food giant Royal Canin and global leader in connected health company Withings. After launching Sweep for Supply Chain in February 2023, the company is committed to creating the best solutions for organizations to improve their ESG and carbon impact while avoiding non-compliance damages. That’s how they can lead – and thrive – in the future low carbon economy.
• • •
About Sweep
Sweep helps businesses track and act on their carbon and ESG data, so they can become Forever Companies.
The data-driven platform makes it easy to understand, manage, and report carbon emissions and ESG metrics. Powerful collaboration features and user-focused design empower staff and entire value chains to grow a sustainable business. And with all the data in one place, its advanced analytics offer comprehensive insights and deliver auditable reports aligned with the latest sustainability regulations and frameworks.
Sweep is B Corp certified and a member of the World Bank’s Carbon Pricing Leadership Coalition, France Invest, and The International Emissions Trading Association. It was selected to join FrenchTech Next 120/40 program and was named “Europe’s fastest growing scale up by Financial Times’ Sifted.
For more information, visit sweep.net
About KPMG France
KPMG in France – market leader in Audit and Consulting – is a 11,000-strong team of professionals dedicated to creating a new prosperity that's set to enhance companies of all sizes. In 2022, a century after its founding, KPMG became a "société à mission” (Purpose-driven company). Its purpose is to work and innovate with passion, to build trust, to combine performance and responsibility and to develop talent at the heart of the economy, territories and society. Thanks to its multidisciplinary model, KPMG combines industry, ESG and digital expertise by relying on its ESG Center of Excellence and its community of 1 000 digital experts to support the growth and transformation projects of its 100,000 clients all over the country.
For more information, visit kpmg.fr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005716/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
